Piramal Pharma

218.51
+18.10
(9.03%)
Market Cap
28,968.92 Cr
EPS
0.14
PE Ratio
494.13
Dividend Yield
0.05 %
Industry
Healthcare
52 Week High
307.90
52 Week low
114.35
PB Ratio
3.36
Debt to Equity
0.70
Add Ratio

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from6 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy100.00 %
100.00 %
Hold0.0 %
0.0 %
Sell0.0 %
0.0 %

Company News

View All News
Caret
neutral
FDA Inspection at Piramal Pharma's Turbhe Facility Results in Form-483 with 6 Observations1 day ago
The US Food and Drug Administration (FDA) conducted a Good Manufacturing Practice (GMP) inspection at Piramal Pharma's facility in Turbhe. Following the inspection, the FDA issued a Form-483 with six observations. These observations primarily focus on procedural improvements and do not involve data integrity issues.
neutral
US FDA Inspection at Piramal Pharma's Turbhe Facility Results in Form-4832 days ago
The US Food and Drug Administration (FDA) conducted a Good Manufacturing Practice (GMP) inspection at Piramal Pharma's facility in Turbhe. Following the inspection, the FDA issued a Form-483 with six observations. These observations primarily focus on areas for procedure improvements and do not relate to data integrity issues.
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,669.30 4,00,520.99 34.13 49,887.20 12.06 9,648 13.77 37.74
5,978.30 1,58,705.08 76.14 8,184.00 0.89 1,600 64.53 51.57
1,479.70 1,19,502.65 23.70 26,520.70 14.17 4,155 47.38 51.15
3,095.95 1,04,781.02 56.64 10,785.70 11.59 1,656 13.54 45.77
1,170.95 97,705.34 18.09 28,905.40 12.36 5,578 1.69 30.83
2,348.45 96,889.27 47.77 10,615.60 19.57 1,942 -16.38 39.42
899.65 90,525.84 19.78 19,831.50 13.82 3,831 29.92 36.77
1,977.50 90,213.07 31.46 20,141.50 19.94 1,936 38.82 38.83
1,121.25 65,122.38 18.72 29,559.20 17.55 3,169 -10.04 42.81
29,429.65 62,535.95 47.37 6,097.20 10.80 1,201 16.01 61.56
Growth Rate
Revenue Growth
14.23 %
Net Income Growth
-109.54 %
Cash Flow Change
107.60 %
ROE
-108.36 %
ROCE
173.33 %
EBITDA Margin (Avg.)
40.67 %

Quarterly Financial Results

Quarterly Financials
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
1,345
1,612
1,709
2,229
1,574
1,777
1,814
2,196
1,802
1,980
2,034
2,591
1,993
2,320
2,233
Expenses
1,197
1,381
1,314
1,733
1,465
1,554
1,629
1,812
1,617
1,646
1,723
2,053
1,747
1,900
1,867
EBITDA
148
231
395
495
109
223
185
384
185
334
312
538
246
420
367
Operating Profit %
9 %
12 %
15 %
19 %
1 %
10 %
5 %
16 %
8 %
14 %
12 %
20 %
10 %
15 %
15 %
Depreciation
136
138
147
165
162
166
164
184
174
185
186
196
185
192
197
Interest
42
49
50
57
62
83
95
104
119
110
106
114
107
108
103
Profit Before Tax
-30
44
198
273
-115
-26
-74
95
-107
40
19
228
-45
120
67
Tax
-2
7
35
69
-6
11
17
45
-9
35
9
126
44
98
63
Net Profit
-28
37
163
204
-109
-37
-90
50
-99
5
10
101
-89
23
4
EPS in ₹
0.00
0.31
1.38
1.72
-0.92
-0.31
-0.76
0.42
-0.83
0.04
0.08
0.77
-0.67
0.17
0.03

Balance Sheet

Balance Sheet
2021
2022
2023
2024
Total Assets
10,900
12,797
14,523
15,312
Fixed Assets
6,106
6,879
7,469
7,990
Current Assets
3,649
4,067
4,836
5,465
Capital Work in Progress
627
1,172
1,419
1,116
Investments
123
267
639
385
Other Assets
4,045
4,478
4,996
5,821
Total Liabilities
10,900
12,797
14,523
15,312
Current Liabilities
2,490
3,033
3,843
4,369
Non Current Liabilities
2,805
3,067
3,906
3,031
Total Equity
5,605
6,697
6,774
7,911
Reserve & Surplus
4,610
5,511
5,580
6,588
Share Capital
995
1,186
1,193
1,323

Cash Flow

Cash Flow
2021
2022
2023
2024
Net Cash Flow
110
-177
-32
166
Investing Activities
-4,464
-1,737
-1,334
-416
Operating Activities
598
766
484
1,005
Financing Activities
3,977
794
818
-422

Share Holding

% Holding
Sept 2022
Oct 2022
Dec 2022
Mar 2023
Jun 2023
Aug 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
34.79 %
0.00 %
34.79 %
34.79 %
34.79 %
35.02 %
35.02 %
35.02 %
35.02 %
34.95 %
34.95 %
34.95 %
FIIs
20.00 %
0.00 %
20.00 %
20.00 %
20.00 %
18.04 %
32.37 %
32.51 %
30.59 %
31.42 %
31.73 %
31.68 %
DIIs
4.86 %
0.00 %
5.28 %
4.99 %
5.49 %
7.83 %
8.02 %
9.68 %
12.12 %
12.95 %
13.81 %
14.10 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
7.42 %
0.00 %
11.80 %
13.94 %
16.77 %
16.81 %
16.95 %
15.57 %
15.13 %
13.94 %
13.29 %
13.29 %
Others
32.92 %
100.00 %
28.14 %
26.29 %
22.95 %
22.30 %
7.64 %
7.22 %
7.14 %
6.74 %
6.22 %
5.98 %
No of Share Holders
1,79,957
1,79,948
2,29,960
2,41,359
2,77,270
2,95,773
2,97,225
2,92,312
2,97,996
3,06,398
3,59,751
4,18,442

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 0.00 0.00 0.00 0.00 0.00 0.56 0.00 0.11 0.00
Dividend Yield (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.84 0.00 0.05 0.00

Corporate Action

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication
9 hours ago
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
1 day ago
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) -US FDA Inspection At Piramal PharmaS Facility Located At Turbh
2 days ago
Intimation For Change In Domain Name And Generic E-Mail ID Of The Registrar And Share Transfer Agent (RTA) Of Company
2 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
3 days ago
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Extension Of Timeline Communicated For Sale Of CompanyS Unit Situated At Thane
Jan 31, 2025, 10:31
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Jan 30, 2025, 20:25
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Jan 30, 2025, 20:13
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Jan 29, 2025, 19:22
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (SEBI Listing Regulations) - Issuance Of Corp
Jan 29, 2025, 17:25
Integrated Filing (Financial)
Jan 28, 2025, 21:08
Announcement under Regulation 30 (LODR)-Investor Presentation
Jan 28, 2025, 20:56
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Jan 28, 2025, 20:53
Announcement under Regulation 30 (LODR)-Change in Directorate
Jan 28, 2025, 20:48
Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Nine Months Ended 31St December 2024
Jan 28, 2025, 20:46
Board Meeting Outcome for Outcome Of Board Meeting Of Piramal Pharma Limited (Company) Held On 28Th January 2025
Jan 28, 2025, 20:42
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (SEBI Listing Regulations)
Jan 27, 2025, 20:05
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Jan 22, 2025, 21:02
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 As Amended (SEBI Listing Regulations) - Issuance Of Corp
Jan 21, 2025, 22:36
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Jan 21, 2025, 11:36
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Jan 13, 2025, 18:48
Board Meeting Intimation for Intimation As Per Regulation 29 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)
Jan 13, 2025, 18:44
Announcement under Regulation 30 (LODR)-Change in Management
Jan 06, 2025, 20:09
Intimation For Change In The Name Of The Registrar And Share Transfer Agent Of The Company
Jan 02, 2025, 19:08
Intimation Regarding Change Of Name Of Registrar And Transfer Agent (RTA) Of The Company From Link Intime India Private Limited To MUFG Intime India Private Limited
Jan 02, 2025, 17:17

Technical Indicators